Source: Pulmo BioTech Inc.
Date: 04 July 2008
Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced the possibility of a new application for its PulmoBind molecular imaging technology.
The PulmoBind product candidates being developed by Pulmo BioTech subsidiary PulmoScience are designed to allow the imaging of the vascular system of the lungs by a diagnostic clinician and thus enable the diagnosis of pulmonary embolism, pulmonary hypertension and lung inflammatory conditions. The way in which this will be achieved is to tag a molecule which preferentially bonds to the inner walls of the capillaries in the lungs with a gamma emitting radionuclide so that the position of the molecules can be seen using a standard Gamma Camera, which is available in all hospitals with a nuclear medicine department.
PulmoScience is now pleased to announce that it has had preliminary success with also tagging its Molecular Imaging candidates with a magnetic resonance contrast agent. If this work is successful it will allow the medical community to also use MRI scanners for lung vascular studies and potentially increase the addressable market for PulmoBind.
